chronic phase.
Introduction
Heparinized bone marrow samples from 10 normals (five males and five females, mean age 37 years), 10 CML chronic Homoharringtonine (HHT), is a cephalotaxine alkaloid 1 phase (CML-CP) (six males and four females, mean age 39 shown to have a clinical efficacy in the treatment of de novo years) and 10 CML blastic phase (CML-BP) (four males and acute myeloid leukemia (AML) either alone or in combination six females, mean age 41 years) patients were studied after with other drugs, mainly cytosine arabinoside (Ara-C). [2] [3] [4] [5] informed consent. CML-CP patients were studied at diagnosis, The inhibition of protein synthesis was identified as the before any therapy. They received, during the chronic phase, most important mechanism of its antileukemic activity. 6, 7 a standard treatment with hydroxyurea, according to white However, the induction of apoptosis was further demonstrated cell count, platelet count, and spleen enlargement, as prein the chronic phase of chronic myeloid leukemia (Ph 1+ CML) viously described. 11 Mononuclear cells were collected after in which HHT, as a single agent, resulted in being also effecsedimentation on Ficoll-Hypaque (Lymphoprep; Nycomed tive in controlling leukocytosis and in producing a sporadic Pharma, Oslo, Norway) T depleted by E-rosetting and karyotypic conversion. 8, 9 deprived of adherent cells, as previously described. 18 The final Because of the activity of HHT on the CML clone its clinical percentage of T cells was less than 1% in each sample. After use in combination with IFN-␣ for the treatment of CML could two washings cells were resuspended in IMDM.
Short-term cell cultures
Correspondence: G Visani, Istituto di Ematologia e Oncologia Medica 'Serà gnoli', Policlinico S, Orsola, Via Massarenti, 9, 40138 BolCells (at a final concentration of 3 × 10 28.8 ± 6.9 22.0 ± 5.4 13.9 ± 5.7
200 ng/ml. HHT at the concentration of 50 ng/ml in combi-50 35.7 ± 7.1 33.0 ± 2.0 31.4 ± 5.1 nation with Ara-C (100 ng/ml) and/or IFN-␣ (1000 U/ml) was 200 54.7 ± 6.2 47.3 ± 2.6 42.4 ± 6.5
further tested. The final suspension was seeded into 24-well plates; after 72 h incubation cells were resuspended and
Values are expressed as m ± s.e.
counted, as previously described. 17, 19, 20 Parallel experiments, with analysis, after 7 days of the colony formation (aggregates composed of more than 50 cells) were performed.
Evaluation of drug combinations: mean fractional product
The activity of the drug combinations was calculated by the mean fractional product as previously reported. [21] [22] [23] Briefly, the ratio between the product of the survival fraction for each agent alone (expected survival) and the survival fraction observed with the drug combination was calculated. Values greater than 1 were considered to show synergism; those less than 0.9-1, ineffective and those of about 1, an additive effect.
Semisolid cultures

Figure 1
Cytotoxic effect of different concentrations of HHT (10,50,200 ng/ml) on normal and CML (both in chronic and in blastic phase) hematopoietic progenitors. Cytotoxic effect is evaluated as CFU-GM colonies were cultured as previously growth inhibition in comparison to controls.
described. 18, 24, 25 Briefly, 1 × 10 5 cells were plated in 1 ml IMDM containing 0.9% methylcellulose, 20% FCS and 10% phytohemoagglutinin-stimulated lymphocyte-conditioned Statistical analysis medium (PHA-LCM) as a source of colony stimulating activity.
HHT was added at the following concentrations (ng/ml): 0.1, Data were analyzed by Student's t-test. P values were con-1,10, alone and in combination (1 ng/ml) with Ara-C (1 ng/ml) sidered significant when Ͻ0.05. and/or IFN-␣ (100 U/ml). Cells were plated in Petri dishes (35 × 10 mm) and CFU-GM colonies (aggregates composed of more than 50 cells) were counted after 14 days of culture at Results 37°C in a fully humidified atmosphere of 5% CO 2 in air. Growth inhibition was calculated as a percentage of control Cytotoxic effect of HHT (no drug in the sample) colony growth.
The cytotoxic effect of HHT is shown in Table 1 and Figure 1 . In particular, at different concentrations of HHT (10, 50, Evaluation of apoptosis 200 ng/ml) the cell growth inhibition on CML-CP was 28.8 ± 6.9, 35.7 ± 7.1 and 54.7 ± 6.2, respectively. Apoptosis was quantitated by flow cytometry, as previously Evaluation of HHT cytotoxic activity on semisolid cultures described.
26 Cells (2.5 × 10 6 ) were incubated in 10 ml IMDM in shown in Table 2 . The IC 50 of HHT in CML-CP and in norplus 10% heat-inactivated fetal calf serum (FCS; Gibco). mal bone marrow cells was 0.6 ng/ml and 1.7 ng/ml, respectSamples were incubated for 24 h with various concentrations of HHT (ng/ml: 10, 100, 200, 1000). Control samples received Table 2 CFU-GM growth inhibition (in comparison to controls) the same amount of media, without drug addition. After 24 h due to different concentrations of HHT of incubation the samples were pelleted and fixed in ethanol 70% for 15 min at 4°C; after three washes in PBS, the cells condensation and fragmentation.
Homoharringtonine, IFN-␣ and Ara-C in chronic myeloid leukemia G Visani et al 626 Table 4 Evaluation of drug combinations on normal hematoively. HHT showed a significantly higher cytotoxic activity on poietic progenitors CML-CP (HHT 1 ng/ml: P = 0.02; HHT 10 ng/ml: P = 0.01).
% of cell growth Mean fractional product
Cytotoxic effects of combinations (Table 3A) ; the same activity was demon- (Table 4A ). In CML-BP only the triple IFN-␣ + HHT 60.9 ± 7.1 1.0 additive combination was able to exert a synergistic effect (Table 5A) . IFN-␣ 65.6 ± 4.9 Ara-C 51.0 ± 6.6 HHT 1 ng/ml 56.0 ± 5.8 IFN-␣ + HHT 38.8 ± 3.1 0.9 additive
Semisolid cultures:
Ara-C + HHT 24.6 ± 7. (Table 3C ). In normal cell progenitors the triple combination exerted an additive effect (MFP = 1.0) while the combination of HHT Table 5 Evaluation of drug combinations on LMC-BP hematowith Ara-C was able to exert an additive/synergistic effect poietic progenitors (MFP = 1.2) ( Table 4C ). Table 3 Evaluation of drug combinations on CML-CP hematopoietic progenitors The induction of apoptosis resulted HHT dose-dependent in Ara-C 81.2 ± 6.9
% of cell growth Mean fractional product
CML-CP and normal cells; at the higher tested drug concen- HHT 10 ng/ml in CML-CP was significant (if compared to control) (P = 0.05). In CML-BP no significant changes were detected (a slight increase only at the higher drug sitivity of normal marrow progenitors should be considered; studies on purified staminal populations could help to explain concentration) (Table 6) . these points and are currently under evaluation in our laboratory. As an alternative, interactions of IFN-␣ on the posttranscriptional modification of P170 should also be Discussion considered. 31, 32 The in vitro synergisms of HHT with Ara-C and/or IFN-␣ on Karyotypic remission is the major goal of therapy in CML, as it has been demonstrated that survival is directly related to the CML-CP cells add further evidence of a selective effect both of HHT and of the combinations HHT + IFN-␣ and HHT + Aradegree of karyotypic conversion.
11 However, a large proportion of patients treated with IFN-␣ still do not achieve a C, in chronic myeloid leukemia in chronic phase, supporting further evaluation in the clinical setting. karyotypic conversion or obtain a minimal karyotypic response (Ph-negative metaphases Ͻ33%). Table 6 Induction of apoptosis in normal bone marrow cells, CML ringtonine (HHT) produces high response rates in Philadelphia chromosome-positive (Ph 1) chronic myelogenous leukemia chronic phase and CML acute phase cells using different concentrations of HHT (10,100,200,1000 ng/ml) (CML 
